Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This is a randomized, double-blind, placebo-controlled, parallel-group, international, multicenter, Phase 3 study to evaluate the efficacy and safety of repeat dosing of benralizumab 30 mg administered subcutaneously (SC) versus placebo in patients with severe nasal polyposis.
Epistemonikos ID: 84fe09e337fb1add87ad54a965d213de1fc6ad6d
First added on: May 06, 2024